Since the discovery of circulating tumor cells in 1869, technological advances in studying
circulating biomarkers from patients' blood have made the diagnosis of nonhematologic …

Results: Recently circulating levels of substance P (SP), soluble CD40 ligand (sCD40L),
tissue inhibitor of matrix metalloproteinases (TIMP)-1, malondialdehyde (MDA), and …

Purpose The Janus kinase 2/signal transducers and activators of transcription (JAK2/STAT)
pathway plays an important role in the pathogenesis of hematologic malignancies. We …

Background Regorafenib inhibits VEGF receptors 1, 2, and 3 and PDGF receptors like other
anti-angiogenic tyrosine-kinase inhibitors approved for treatment of advanced renal-cell …

Proteomics has the potential to identify pharmacodynamic (PD) biomarkers for similarity
assessment of proposed biosimilars without relying on clinical efficacy end points. In this …

Background Excess adiposity at diagnosis and weight gain during chemotherapy is
associated with tumour recurrence and chemotherapy toxicity. We assessed the efficacy of …

The development of minimally invasive and low-cost assay enabling early diagnosis,
treatment response and prognosis in cancer patients may provide a promising alternative to …

Background Effective anticancer therapy is thought to involve induction of tumour cell death
through apoptosis and/or necrosis.[18 F] ICMT-11, an isatin sulfonamide caspase-3/7 …

Circulating free nucleic acids; cell free DNA and circulating micro-RNA, are found in the
plasma of patients with hematologic and solid malignancies at levels higher than that of …

Background Systemic failure remains a challenge in rectal cancer. We investigated the
possible systemic anti-tumour immune activity invoked within oxaliplatin-based neoadjuvant …